Research programme: photodynamic therapies - Provectus PharmaceuticalsAlternative Names: PH-12
Latest Information Update: 25 Nov 2010
At a glance
- Originator Provectus Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer; Skin disorders
Most Recent Events
- 06 Mar 2008 Preclinical trials in Skin disorders in USA (unspecified route)
- 06 Mar 2008 Preclinical trials in Cancer in USA (unspecified route)